Year None2023202220212020201920182017201620152014 May 25 Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma May 25 Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations May 21 Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of Medicine May 19 High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023 May 18 Regeneron Announces Investor Conference Presentations May 18 Regeneron Applauds Supreme Court’s Unanimous Opinion Striking Down Amgen’s PCSK9 Patent Claims and Supporting Scientific Innovation May 4 Regeneron Reports First Quarter 2023 Financial and Operating Results May 2 Regeneron to Highlight New and Updated Clinical Data at ASCO Showcasing Breadth of Cancer Research Apr 26 Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy Apr 17 Regeneron Announces Retirement of Board Chair, Dr. P. Roy Vagelos, Accomplished Physician-Businessman and Industry Luminary Current page 1 Page 2 Page 3 Page 4 Next page › Last page »